4.7 Article

Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy

Journal

ANNALS OF SURGERY
Volume 257, Issue 6, Pages 1079-1088

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SLA.0b013e318283a4d1

Keywords

colorectal liver metastases; overall survival; pathologic response; radiologic morphologic response; systemic therapy

Categories

Funding

  1. National Institutes of Health through MD Anderson's Cancer Center Support grant [CA016672]

Ask authors/readers for more resources

Objective: To determine the impact of surgical margin status on overall survival (OS) of patients undergoing hepatectomy for colorectal liver metastases after modern preoperative chemotherapy. Background: In the era of effective chemotherapy for colorectal liver metastases, the association between surgical margin status and survival has become controversial. Methods: Clinicopathologic data and outcomes for 378 patients treated with modern preoperative chemotherapy and hepatectomy were analyzed. The effect of positive margins on OS was analyzed in relation to pathologic and computed tomography-based morphologic response to chemotherapy. Results: Fifty-two of 378 resections (14%) were R1 resections (tumor-free margin <1 mm). The 5-year OS rates for patients with R0 resection (margin >= 1 mm) and R1 resection were 55% and 26%, respectively (P = 0.017). Multivariate analysis identified R1 resection (P = 0.03) and a minor pathologic response to chemotherapy (P = 0.002) as the 2 factors independently associated with worse survival. The survival benefit associated with negative margins (R0 vs R1 resection) was greater in patients with suboptimal morphologic response (5-year OS rate: 62% vs 11%; P = 0.007) than in patients with optimal response (3-year OS rate: 92% vs 88%; P = 0.917) and greater in patients with a minor pathologic response (5-year OS rate: 46% vs 0%; P = 0.002) than in patients with a major response (5-year OS rate: 63% vs 67%; P = 0.587). Conclusions: In the era of modern chemotherapy, negative margins remain an important determinant of survival and should be the primary goal of surgical therapy. The impact of positive margins is most pronounced in patients with suboptimal response to systemic therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Meeting Abstract Oncology

Comprehensive landscape of BRAF variant classes, clonalities, and comutations in metastatic colorectal cancer using ctDNA profiling

Benny Johnson, Dong Yang, Hiba I. Dada, Leylah Drusbosky, Scott Kopetz

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Outcomes of IBD-associated colorectal cancer and implications in early-onset colorectal cancer

Oscar Villarreal, Fadl A. Zeineddine, Ray Chacko, Christine Megerdichian Parseghian, Benny Johnson, Jason Willis, Michael Sangmin Lee, Van K. Morris, Arvind Dasari, Kanwal Pratap Singh Raghav, Michael J. Overman, Y. Nancy You, Yinghong Wang, Dipen M. Maru, John Paul Y. C. Shen, Scott Kopetz

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US)

Arvind Dasari, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Halil Sahin, Dustin A. Deming, Agop Philip Philip, Theodore S. Hong, Norman Wolmark, Greg Yothers, Thomas J. George, Christopher Hanyoung Lieu

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA)

Van K. Morris, Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal, Patrick M. Boland, Dustin A. Deming, Aaron James Scott, Howard John Lim, Theodore S. Hong, Norman Wolmark, Thomas J. Georgenrg

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Minimal residual disease assessment in colorectal cancer (MiRDA-C)

Arvind Dasari, Maen Abdelrahim, Jared David Acoba, Krishna Chaitanya Alluri, Tomislav Dragovich, Syed Mohammad Ali Kazmi, Benjamin Leon Musher, Ryan Sun, Lucas Wong, Y. Nancy You, Robert Anthony Zaiden, Scott Kopetz

JOURNAL OF CLINICAL ONCOLOGY (2022)

Letter Oncology

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Sajid Khan, Janet Wiegand, Peiyi Zhang, Wanyi Hu, Dinesh Thummuri, Vivekananda Budamagunta, Nan Hua, Lingtao Jin, Carmen J. Allegra, Scott E. Kopetz, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou

Summary: KRAS(G12C) mutation is associated with tumor identification and its sensitivity to current treatments. This study demonstrates the synergistic effect of sotorasib and DT2216 combination therapy on certain KRAS(G12C) tumor cell lines, leading to enhanced efficacy in treating these tumors.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Article Oncology

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer

Marwan Fakih, Huakang Tu, Hil Hsu, Shivani Aggarwal, Emily Chan, Marko Rehn, Victoria Chia, Scott Kopetz

Summary: This article describes clinicopathologic characteristics, treatment patterns, overall survival, and real-world progression-free survival in patients with metastatic colorectal cancer and specific KRAS mutations. The results show that patients with the KRAS p.G12C mutation have poor treatment outcomes and potential prognostic implications.

ONCOLOGIST (2022)

Article Oncology

Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer

Van Morris, Bryan Kee, Michael Overman, Arvind Dasari, Kanwal Raghav, Benny Johnson, Christine Parseghian, Robert A. Wolff, Naveen Garg, Cathy Eng, Scott Kopetz

Summary: The study analyzed the characteristics and survival rates of patients with BRAF(V60)(0E) mutated metastatic CRC, finding significant differences in clinical/pathologic features between patients with favorable and poor outcomes, including hepatic involvement, metachronous metastases, and treatment modalities. While the overall prognosis for most patients with BRAF(V60)(0E) mutated metastatic CRC remains poor, a small subset may achieve exceptionally favorable long-term survival.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2022)

Article Gastroenterology & Hepatology

Use and outcome of minimally invasive pancreatic surgery in the European E-MIPS registry

Nicky van der Heijde, Frederique L. Vissers, Alberto Manzoni, Giuseppe Zimmitti, Joaquim Balsells, Frederik Berrevoet, Bergthor Bjornsson, Peter van den Boezem, Ugo Boggi, Svein O. Bratlie, Fernando Burdio, Andrea Coratti, Mathieu D'Hondt, Carlos D. Del Pozo, Safi Dokmak, Regis Fara, Mehmet F. Can, Sebastiaan Festen, Antonello Forgione, Claus Fristrup, Sebastien Gaujoux, Bas Groot Koerkamp, Thilo Hackert, Igor E. Khatkov, Tobias Keck, Hanna Seppanen, Daan Lips, Misha Luyer, Gabriella Pittau, Manuel Maglione, I. Quintus Molenaar, Patrick Pessaux, Geert Roeyen, Olivier St-Marc, Santiago S. Cabus, Hjalmar van Santvoort, George van der Schelling, Mario Serradilla-Martin, Francois-regis Souche, Miguel A. Suarez Munoz, Marco Marino, Marc G. Besselink, Mohammed Abu Hilal

Summary: The E-MIPS registry collects data on laparoscopic and robotic minimally invasive pancreatic surgery (MIPS) across Europe. This study analyzed the first year of the registry and found that MIDP was performed in about half of the patients, mainly using laparoscopy, while MIPD was performed in about a quarter of the patients, more often using the robotic approach. There were only a minority of centers that met the Miami guideline volume criteria for MIPD.
Article Oncology

Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance)

Kanwal Raghav, Fang-Shu Ou, Alan P. Venook, Federico Innocenti, Ryan Sun, Heinz-Josef Lenz, Scott Kopetz

Summary: Clinical trial updates allow for dissemination of additional results from studies where the primary end point has already been reported. This study aimed to determine the prevalence of acquired genomic alterations (Acq-GAs) on anti-EGFR-chemotherapy compared to anti-VEGF-chemotherapy and later-line anti-EGFR-antibody therapy in metastatic colorectal cancer (mCRC). The findings indicate divergent resistance mechanisms with rare occurrence of Acq-GAs with up-front use of anti-EGFR-chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Editorial Material Oncology

Diverticular disease and cancer risk: More than a gut feeling

Veronika Fedirko, Scott Kopetz, Carrie R. Daniel

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Editorial Material Oncology

Truncal Dynamics May Trump: Serial ctDNA to Predict Early Therapeutic Response

Madhulika Eluri, Scott Kopetz, Christine M. Parseghian

Summary: The use of serial ctDNA in metastatic colorectal cancer has the potential to refine patient selection, reduce chemotherapy toxicity, and assess emerging resistance mechanisms for novel therapeutic strategies. However, important questions remain regarding its validation as a predictive biomarker of treatment response.

CLINICAL CANCER RESEARCH (2023)

Letter Oncology

Reply to Y. Yu et al

Kanwal Raghav, Scott Kopetz, Ying Yuan

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors

Blessie Elizabeth Nelson, Apostolia M. Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Anil K. Sood, Jordi Rodon, Daniel D. Karp, George Blumenschein, Scott Kopetz, Shubham Pant, Sarina A. Piha-Paul

Summary: This study evaluated the combination of bevacizumab, temsirolimus, and valproic acid in patients with advanced malignancies and found modest efficacy but significant toxicity. The study is the first to evaluate this combination and suggests potential for anticancer activity, but careful management of toxicity is necessary for future development.

ONCOLOGIST (2023)

Article Oncology

Laparoscopic Right Hemihepatectomy after Future Liver Remnant Modulation: A Single Surgeon's Experience

Tijs J. Hoogteijling, Jasper P. Sijberden, John N. Primrose, Victoria Morrison-Jones, Sachin Modi, Giuseppe Zimmitti, Marco Garatti, Claudio Sallemi, Mario Morone, Mohammad Abu Hilal

Summary: This study evaluated the safety and feasibility of Laparoscopic right hemihepatectomy (L-RHH) after Future liver remnant modulation (FLRM), compared to ex novo L-RHH. The results showed that L-RHH after FLRM is more technically complex, with longer operative time and Pringle duration, but it remains safe and feasible in experienced hands.

CANCERS (2023)

No Data Available